What is it about?
This study explored the effectiveness of two non-invasive tests, the Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) and the Fibrosis-4 (FIB-4) Index, in diagnosing cirrhosis associated with hepatitis C virus infection. The research involved 906 individuals living with hepatitis C. The performance of each test was evaluated on its own and in combination.
Featured Image
Why is it important?
This article is crucial because it introduces a more accurate way to identify cirrhosis in individuals with hepatitis C. By assessing the APRI and FIB-4 Index individually and then combining them sequentially, the study found that the combined approach significantly improved diagnostic performance. This is valuable information for healthcare professionals, providing a more effective method for diagnosing cirrhosis in hepatitis C patients.
Perspectives
From a personal perspective, this research represents a promising step forward in improving the diagnosis of cirrhosis in individuals with hepatitis C. The sequential combination of APRI and FIB-4 demonstrated enhanced sensitivity and specificity, offering a more reliable method for healthcare providers to identify cirrhosis early. This advancement has the potential to lead to better patient outcomes and more targeted interventions, highlighting the importance of ongoing research in enhancing diagnostic tools for liver health in individuals with hepatitis C.
Dr. Mohd Azri Mohd Suan
Ministry of Health Malaysia
Read the Original
This page is a summary of: Diagnostic performance of two non-invasive biomarkers used individually and in sequential combination for cirrhosis associated with hepatitis C virus infection, Scientific Reports, November 2022, Springer Science + Business Media,
DOI: 10.1038/s41598-022-24612-9.
You can read the full text:
Contributors
The following have contributed to this page
